DBV Technologies SA
PAR:DBV

Watchlist Manager
DBV Technologies SA Logo
DBV Technologies SA
PAR:DBV
Watchlist
Price: 3.425 EUR -4.86% Market Closed
Market Cap: 667.7m EUR

Operating Margin
DBV Technologies SA

-3 210.5%
Current
-1 734%
Average
-4.2%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-3 210.5%
=
Operating Profit
-122m
/
Revenue
3.8m

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
FR
DBV Technologies SA
PAR:DBV
667.7m EUR
-3 211%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-17 527%
US
Abbvie Inc
NYSE:ABBV
407.1B USD
33%
US
Amgen Inc
NASDAQ:AMGN
179.3B USD
34%
US
Gilead Sciences Inc
NASDAQ:GILD
157.2B USD
39%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
116.6B USD
39%
US
Epizyme Inc
F:EPE
94.1B EUR
-370%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
82.5B USD
28%
AU
CSL Ltd
ASX:CSL
85.1B AUD
26%
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
53.5B USD
8%
NL
argenx SE
XBRU:ARGX
44.2B EUR
22%
No Stocks Found

DBV Technologies SA
Glance View

Market Cap
667.7m EUR
Industry
Biotechnology

DBV Technologies SA is a clinical-stage biopharmaceutical company, which engages in the research and development of epicutaneous immunotherapy products. The company is headquartered in Montrouge, Ile-De-France. The company went IPO on 2012-03-29. The firm's therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin. The company dedicates its technology to treat patients, including infants and children, suffering from severe food allergies, for whom safety is paramount, since the introduction of the offending allergen into their bloodstream can cause severe or life-threatening allergic reactions, such as anaphylactic shock. The firm's product portfolio for allergy treatments consists of Viaskin Peanut, Viaskin Milk and Viaskin Egg. The firm operates one subsidiary DBV Technologies Inc. in the United States.

DBV Intrinsic Value
6.676 EUR
Undervaluation 49%
Intrinsic Value
Price
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-3 210.5%
=
Operating Profit
-122m
/
Revenue
3.8m
What is the Operating Margin of DBV Technologies SA?

Based on DBV Technologies SA's most recent financial statements, the company has Operating Margin of -3 210.5%.

Back to Top